Qiagen NV provided earnings guidance for the first quarter and fiscal year 2013. For the quarter, the company expects total net sales of 2-3% CER, adjusted diluted EPS of $0.22-0.23 and adjusted tax rate of 24%.

For the fiscal year 2013, the company expects to deliver higher net sales and adjusted earnings in 2013, building on the strong performance in 2012. For the full year, total net sales are expected to rise about 5-6% CER on a mix of contributions from organic growth of the business portfolio and from AmniSure. Adjusted diluted earnings per share are expected to rise to approximately $1.16 to $1.18 for full-year 2013. This guidance takes into account dilution of approximately $0.02 to $0.03 per share from the net impact of the new U.S. medical device tax and higher interest expenses incurred through the U.S. private placement in October 2012 partially offset by effects of the share repurchase program. These expectations do not take into account potential sequestration actions in the U.S., which could lead to further reductions in government funding for life sciences research. Also excluded are any acquisitions that could be completed in 2013.